Join to View Full Profile
950 Ryland StReno, NV 89502
Phone+1 775-329-0286
Fax+1 775-329-4243
Dr. Khanani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Texas Tech University Health Sciences Center at LubbockResidency, Ophthalmology, 2005 - 2008
Baylor College of MedicineInternship, Internal Medicine, 2004 - 2005- Texas Tech University Health Sciences Center School of MedicineClass of 2004
Certifications & Licensure
NV State Medical License 2010 - 2027
TX State Medical License 2007 - 2012
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Ocriplasmin Research to Better Inform Treatment (ORBIT) Start of enrollment: 2014 May 01
- A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA Start of enrollment: 2014 Aug 01
- Cooling Anesthesia for Intravitreal Injection Start of enrollment: 2018 Nov 30
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsPhase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration.David A Eichenbaum, Nancy Holekamp, Arshad M Khanani, Dante Pieramici, Vrinda Hershberger
American Journal of Ophthalmology. 2025-07-01 - Bilateral paracentral acute middle maculopathy associated with open mitral valve repair.Humza Sulahria, Ohidul Mojumder, Greggory M Gahn, Arshad M Khanani
American Journal of Ophthalmology Case Reports. 2025-06-01 - Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE.Roger A Goldberg, Florie A Mar, Karl Csaky, Manuel Amador, Arshad M Khanani
Ophthalmology. Retina. 2025-06-01
Journal Articles
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationArshad M Khanani, Sunil S Patel, Philip J Ferrone, Pravin U Dugel, JAMA Ophthalmology
Authored Content
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Press Mentions
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025June 23rd, 2025- RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025May 12th, 2025
- Port System Cuts Injection Burden in Diabetic Eye DiseaseMarch 11th, 2025
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
